Myositis Autoantibodies: A Comparison of Results from the Oklahoma Medical Research Foundation Myositis Panel to the Euroimmun Research Line Blot.
The ability to accurately assay a broad range of well-defined autoantibody specificities in myositis patients is imperative for clinical phenotyping and patient care. In myositis research, the systematic serotyping of patient cohorts is often performed using various research assays, and understanding the relationship between research testing and clinical testing is paramount to advancing the field of myositis. An increasingly popular research multiplex antibody assay platform was developed by Euroimmun (EUROLINE Autoimmune Inflammatory Myopathies 16 Ag IgG, Lubeck, Germany) for myositis-specific and associated autoantibodies. Prior research has suggested that the inter-rater reliability of Euroimmun compared to in-house immunoprecipitation methods (considered the gold standard) is reasonable, with the possible exception of TIF1γ [1-4]. In this communication, we share our experience comparing serological results obtained for clinical purposes with a commercial myositis autoantibody panel (the traditional Oklahoma Medical Research Foundation Myositis panel, "OMRF") and serologies obtained for research purposes using the Euroimmun Myositis panel. This article is protected by copyright. All rights reserved.